Prostate Cancer Foundation-Department of Veterans Affairs Partnership: A Model of Public-Private Collaboration to Advance Treatment and Care of Invasive Cancers
Rebecca Levine is Vice President, Government Affairs and National Director of the Veterans Health Initiative; Ruwanthi Ekanayake is a Consultant; Ashley Martin is Program Assistant, Government Affairs; Kyle Dickson and Kayla McGarrell are Research Assistants, Government Affairs; Howard Soule is Executive Vice President, Chief Science Officer; Andrea Miyahira is Director, Global Research and Scientific Communications; Rebecca Campbell is Manager of Medical Content; Thomas Johnson is Assistant Chief of Staff; and Jonathan Simons is President and Chief Executive Officer; all at the Prostate Cancer Foundation. Correspondence: Rebecca Levine (rlevine@pcf.org)
Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.
The PCF-VA partnership serves as an example of a public-private health partnership pursuing strategic pathways and bold goals to ensure that every eligible veteran has access to precision oncology. These pathways include advocacy on the part of executive leadership, recognizing existing economies of scale, building compelling narratives to maximize funding, creating flexible requirements, and facilitating a robust, resource-rich scientific network. This partnership already has opened doors to future initiatives and continues to adapt to a rapidly changing health landscape. The discussed strategies have the potential to inform future health initiatives and showcase how a systemic approach to eradicating health inequities can greatly benefit underserved communities.
The success of the PCF-VA partnership represents more than just an efficient partnership model. The partnership’s emphasis on veterans, who exemplify service, highlights the extent to which cancer patients sacrifice to contribute to medical research. This service necessitates a service in kind: all health stakeholders share the responsibility to rapidly advance therapies and care, both to honor the patients who have come before, and to meet the needs of patients with treatment resistant forms of the disease urgently awaiting precision breakthroughs and cures.